Table 2.
Multivariable predictors of any radiographic progression and progression ≥ 4 SHS Units/Year
|
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any radiographic progression | ≥ 4 SHS Units/Year | |||||||||
|
|
||||||||||
| Model 1 | Model 2 | Model 1 | Model 2 | Model 3 | ||||||
| OR | P | OR | P | OR | P | OR | P | OR | P | |
|
|
|
|||||||||
| anti-PAD4-IgG1 | 2.83 | 0.009 | 2.93 | 0.036 | 6.21 | <0.001 | 5.39 | 0.006 | 4.88 | 0.005 |
| Male vs female | 0.40 | 0.034 | 0.48 | 0.30 | ||||||
| anti-PAD2 | 0.26 | 0.023 | 0.34 | 0.19 | ||||||
| Average IL-6 | 1.06 | 0.010 | 1.04 | 0.002 | 1.03 | 0.004 | ||||
| Baseline pain | 1.03 | 0.006 | 1.01 | 0.52 | ||||||
| Baseline SHS>0 | 4.97 | 0.001 | 2.10 | 0.37 | ||||||
|
|
|
|||||||||
| AUC (95% CI) | 0.596 (0.528–0.663) | 0.817 (0.749–0.887) | 0.708 (0.591–0.824) | 0.868 (0.795–0.929) | 0.851 (0.777–0.915) | |||||
SHS, Sharp/van der Heijde score; OD, odds ratio; PAD, peptidylarginine deiminase; IL-6, interleukin-6; AUC, area under the curve.